Lapatinib Ditosylate
Lapatinib ditosylate is a dual tyrosine kinase inhibitor for HER2-positive breast cancer. The core quinazoline structure (aromatic heterocyclic with nitrogen) places it under HTS 2933.99.75.00 as a drug.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If organo-inorganic classification
Chapter notes specify organo-inorganic compounds with metals go to heading 2931.
If as veterinary medicine
Veterinary medicaments in dosage form classified under different Chapter 30 subheading.
If ketone function emphasis
If acyclic ketone characteristic dominates, classifies under heading 2914.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right HTS code — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Declare as 'Lapatinib ditosylate monohydrate' if hydrated form per CoA
• Include bioequivalence data if generic import competing with originator
Related Products under HTS 2933.99.75.00
Imatinib Mesylate
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Erlotinib Hydrochloride
Erlotinib hydrochloride is an epidermal growth factor receptor (EGFR) inhibitor used in non-small cell lung cancer treatment. As a quinazoline derivative (aromatic heterocycle with nitrogen), it qualifies under HTS 2933.99.75.00 for aromatic heterocyclic drugs.
Nilotinib Hydrochloride
Nilotinib hydrochloride treats imatinib-resistant chronic myelogenous leukemia. As a pyrimidine derivative with aromatic nitrogen heterocycles, it falls under the 'drugs: other' provision of HTS 2933.99.75.00.
Gefitinib
Gefitinib is an EGFR tyrosine kinase inhibitor for lung cancer treatment. This 4-anilinoquinazoline (aromatic N-heterocycle) is classified as a bulk pharmaceutical drug under HTS 2933.99.75.00.
Osimertinib Mesylate
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Brigatinib
Brigatinib is an ALK inhibitor for lung cancer treatment. This macrocyclic aromatic nitrogen-heterocycle drug substance imports under HTS 2933.99.75.00.